SupplementalReference
1. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R et al. A pharmacogenetic study to investigatetherole
of dietarycarcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002;23:1839–49.
2.Hamada GS, Sugimura H, Suzuki I et al. The heme-binding region polymorphism of cytochromeP450IA1
(CypIA1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer inRio de
Janeiro. Cancer EpidemiolBiomarkers Prev.1995;4:63–7.
3.Singh R, Haridas N, Shah F, Patel J, Shukla S, Patel P.Gene polymorphisms, tobacco exposure and oral
cancersusceptibility: a study from Gujarat, West India.Oral Dis. 2013; doi: 10.1111/odi.12079.
4.Han G, Ma Y, Liu P, Wei X, Zhang X, Zhu F.Quantitative synthesis of the association between the
cytochromeP450 1A1 Ile462Valpolymorphism and prostate cancer risk.Tumour Biol. 2013;34:1511–6.
5.Islam MS, Ahmed MU, Sayeed MS, Maruf AA, Mostofa AG, Hussain SM, Kabir Y, Daly AK, Hasnat A.Lung
cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the
Bangladeshi population.Clin Chim Acta. 2013;416:11–9.
6.Raimondi S, Boffetta P, Anttila S, Bröckmoller J, Butkiewicz D, Cascorbi I:Metabolic gene polymorphisms
and lung cancer risk in non-smokers. Anupdate of the GSEC study. Mutat Res. 2005;592:45–57.
7. Ishibe N, Stampfer M, Hunter DJ, Hennekens C, Kelsey KT. A prospective study of cytochrome P4501A1
polymorphisms and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev.2000;9:855–6.
8.Yamaguti GG, Lourenço GJ, Silveira VS, Tone LG, Lopes LF, Lima CS. Increased risk for acute
lymphoblastic leukemia in children with cytochrome P450A1 (CYP1A1)- and NAD(P)H:quinine
oxidoreductase 1 (NQO1)-inherited gene variants. Acta Haematol. 2010;124:182–4.
9. Atinkaya C, Taspinar M, Sakiragaoglu O, Oz G, Yazici U, Oztuna D, Tastepe I, Sunguroglu A. The effect of
CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: A case–control study.Hum Exp
Toxicol. 2012;31:1074–80.
10. Vijayalakshmi K, Vettriselvi V, Krishnan M, Shroff S, Jayanth VR, Paul SF. Cytochrome p4501A1 gene
variants as susceptibility marker for prostate cancer. Cancer Biomark. 2005;1:251–8.
11. Seremak-Mrozikiewicz A, Drews K, Semczuk A, et al. CYP1A1 alleles in female genital cancers in the Polish
population. Eur J Obstet Gynecol Reprod Biol. 2005;118:246–50.
12. Leichsenring A, Losi-Guembarovski R, Maciel ME, Losi-Guembarovski A, Oliveira BW, Ramos G,
Cavalcanti TC, BicalhoMG, Cavalli IJ, Colus IM, Ribeiro EM. CYP1A1 and GSTP1polymorphisms in an
oral cancer case–control study. Braz J MedBiol Res. 2006;39:1569–74.
13. Wang N, Wu Y, Zhou X, Wu Y.Association between genetic polymorphism of metabolizing enzymes and
DNA repairing enzymes and thesusceptibility of lung cancer in Henan population. Wei Sheng Yan Jiu.
2012;41:251–6.
14. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y.Genetic polymorphisms involved in carcinogen
metabolism and DNA repair and lung cancer risk in aJapanese population. J Thorac Oncol. 2012;7:954–62.
15. Reding KW, Chen C,Lowe K, Doody DR, Carlson CS, Chen CT, Houck J, Weiss LK, Marchbanks PA,
Bernstein L, Spirtas R,McDonald JA, Strom BL, Burkman RT, Simon MS, Liff JM, Daling JR, Malone KE.
Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes
Control.2012;23:671–81.
16. Matei MC, Negură L, Liliac L,Negură A, Azoicăi D.Validation of PCR-RFLP techniques for the evaluation
of codon 72 of p53 and CYP1A1 gene'spolymorphisms in relation with ovarian cancer in a Romanian
population. Rom J Morphol Embryol. 2012;53:47–54.
17.Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M. Case–controlstudy of oral and oropharyngeal cancer in
whites and genetic variationin eight metabolic enzymes. Head Neck. 2008;30:1139–47.
18. Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S,Arzani D, et al. Polymorphisms inmetabolic genes, their combinationand interaction with tobacco smoke and alcohol consumptionand risk ofgastric cancer: a case–control study in an Italianpopulation. BMC Cancer. 2007;7:206.
19. Chen J, Cheng M, Yi L,Jiang CB.Relationship between CYP1A1 genetic polymorphisms and renal cancer in
China. Asian Pac J Cancer Prev. 2011;12:2163–6.
20. Lee K, Caceres D, Varela N, Csendes DA, Rios RH, Quinones SL(2006) Allelic variants of cytochrome
P4501A1 (CYP1A1), glutathioneS transferase M1 (GSTM1) polymorphisms and their associationwith
smoking and alcohol consumption as gastric cancersusceptibility biomarkers. Rev Med Chil.
134:1107–15.
21. Ahmad ST, Arjumand W, Seth A, Nafees S, Rashid S, Ali N, Hamiza OO, Sultana S.Risk of renal cell
carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6enzymes. Urol
Oncol.2012; [Epub ahead of print].
22. Szanyi I, Ráth G, Móricz P,Somogyvári K, Révész P, Gerlinger I, Orsós Z, Ember I, KissI.Effects of
cytochrome P450 1A1 and uridine-diphosphate-glucuronosyltransferase 1A1 allelic polymorphisms
on the risk of development and the prognosis of head and neck cancers. Eur J Cancer Prev. 2012;21:560–8.
23. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC,Speizer FE, Kelsey KT, Hunter DJ.
Cigarette smoking,cytochrome P450 1A1 polymorphisms, and breast cancer risk inthe Nurses’ Health Study.
Cancer Res. 1998;58:667–71.
24. Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, Zomawia E, Verma Y,Kapur S, Saxena
S.Multiple analytical approaches reveal distinct gene-environment interactions in smokersand non smokers
inlung cancer. PLoS One. 2011;6:e29431.
25. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S,Perret C, Lacroix A, Labuda D, Sinnett D.
Genetic susceptibilityto breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and
gene-environment interactions.Int J Cancer.2001;92:220–225
26. Timofeeva MN, Kropp S, Sauter W, Beckmann L et al. CYP450 polymorphisms as risk factorsfor early-onset
lung cancer: genderspecific differences. Carcinogenesis. 2009;30:1161–9.
27. Casson AG, Zheng Z, Chiasson Det al. Associations between genetic polymorphisms of Phase I and II
metabolizing enzymes，p53 and susceptibility to esophageal adenocarcinoma. Cancer DetectPrevent. 2003;
27:139–46．
28. Wang D, Su M, Tian D, Liang S, Zhang J.Associations between CYP1A1 and CYP2E1 polymorphisms and
susceptibility to esophageal cancer inChaoshan and Taihang areas of China. Cancer Epidemiol.
2012;36:276–82.
29. Wang G, Hou J, MaL, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H, Cao G.Risk factor for clear cell
renal cell carcinoma in Chinese population: a case–control study. Cancer Epidemiol. 2012;36:177–82.
30.Fritsche E, Bruning T, Jonkmanns C, Ko Y, Bolt HM et al.Detection of cytochrome P450 1B1 Bfr I
polymorphism: genotype distribution in healthy German individuals and in patients with colorectal
carcinoma.Pharmacogenetics 1999;9:405–8.
31. KimHN, Kim NY, Yu L, Tran HT, Kim YK, Lee IK, Shin MH, Park KS, Choi JS, Kim HJ.Association of
GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status. Leuk Lymphoma.
2012;53:681–7.
32.Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined
genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res. 1992;83:866–70.
33. Taioli E, Crofts F, Trachman J, Demopoulos R, Toniolo P, Garte SJ. A specific African-American CYP1A1
polymorphism is associated with adenocarcinoma of the lung. Cancer Res. 1995;55:472–3.
34. Lourenço GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1
polymorphisms, tobacco and alcohol status and risk of head and necksquamous cell carcinoma. Tumour Biol.
2011;32:1209–15.
35. Naushad SM, Reddy CA, Rupasree Y, Pavani A, Digumarti RR,Gottumukkala SR, Kuppusamy P, Kutala VK.
Cross-talk between one-carbon metabolism and xenobiotic metabolism: implications on oxidative DNA
damage and susceptibility to breast cancer. Cell Biochem Biophys. 2011;61:715–23.
36.Nakachi K, Imai K, Hayashi S, Kawajiri K: Polymorphisms of the CYP1A1and glutathione S-transferase
genes associated with susceptibility tolung cancer in relation to cigarette dose in a Japanese population.
Cancer Res. 1993;53:2994–9.
37. Alexandrie AK, Sundberg MI, Seidegård J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with
special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and
histological cancer types. Carcinogenesis. 1994;15:1785–90.
38. Sugimura H, Hamada GS, Suzuki I, Iwase T, Kiyokawa E, Kino I, Tsugane S. CYP1A1 and CYP2E1
polymorphism and lung cancer, case–control study in Rio de Janeiro, Brazil. Pharmacogenetics.
1995;5:S145-8.
39. Öztürk T, Kahraman ÖT, Toptaş B, Kisakesen Hİ, Çakalir C, Verim L, Öztürk O, İsbir T. The effect of
CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkishpopulation. In Vivo.
2011;25:663–8.
40. Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, Yamamoto S, Yokota J.Contribution of the TP53,
OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cellcarcinoma. J Thorac Oncol.
2011;6:813–7.
41. Katoh T, Inatomi H, Nagaoka A, Sugita A. Cytochrome P4501A1 gene polymorphism and homozygous
deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis.
1995;16:655–7.
42. Swinney RM, Beuten J, Collier AB 3rd, Chen TT, Winick NJ, Pollock BH, Tomlinson GE.Polymorphisms in
CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children.Cancer Epidemiol
Biomarkers Prev. 2011;20:1537–42.
43. Cantlay AM, Lamb D, Gillooly M, Norrman J, Morrison D, Smith CA, Harrison DJ. Association between the
CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. Clin Mol Pathol.
1995;48:M210–4.
44. Bianchino G, Cittadini A, Grieco V, Traficante A, Zupa A, Improta G, Aieta M,Sgambato A. Polymorphisms
of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern Italian population:a case–control
study. Anticancer Res. 2011;31:1359–65.
45.Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T,
Michalek AM, Harrington A, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic
polymorphisms and postmenopausal breast cancer risk. Cancer Res. 1995;55:3483–5.
46. Nakachi K, Hayashi S, Kawajiri K, Imai K. Association of cigarette smoking and CYP1A1 polymorphisms
with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis. 1995;16:2209–13.
47. Wang Q, Li H, Tao P, Wang YP, Yuan P, Yang CX, Li JY, Yang F, Lee H, Huang Y.Soy isoflavones, CYP1A1,
CYP1B1, and COMT polymorphisms, and breast cancer: a case–control study insouthwestern China. DNA
Cell Biol. 2011;30:585–95.
48. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is
associated with breast cancer in African-American women. Cancer Res. 1995;55:3757–8.
49. Kihara M, Kihara M, Noda K. Risk of smoking for squamous and small cell carcinomas of the lung
modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population.
Carcinogenesis. 1995;16:2331–6.
50. Houlle S, Charbonnier F,Houivet E, Tinat J, Buisine MP, Caron O, Benichou J, Baert-Desurmont S, Frebourg
T.Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet.
2011;19:887–92.
51. Katoh T. J UOEH. Application of molecular biology to occupational health field--the frequency of gene
polymorphismof cytochrome P450 1A1 and glutathione S-transferase M1 in patients with lung, oral and
urothelial cancer. 1995;17:271–8.
52. Matthias C, Bockmühl U, Jahnke V, Jones PW, Hayes JD, Alldersea J, Gilford J, Bailey L, Bath J, Worrall SF,
Hand P, Fryer AA, Strange RC. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and
glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in
upper aerodigestive tract cancers. Pharmacogenetics. 1998;8:91–100.
53. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, Miki H, Fujii T, Yoshino K, Kusuoka H,
Monden M. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck
squamous-cell carcinoma. Int J Cancer. 1999;80:685–8.
54. Brockmöller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine
N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome
P450 enzymes as modulators of bladder cancer risk. Cancer Res. 1996;56:3915–25.
55. Laden F, Ishibe N, Hankinson SE, Wolff MS, Gertig DM, Hunter DJ, Kelsey KT. Polychlorinated biphenyls,
cytochrome P450 1A1, and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers
Prev. 2002;11:1560–5.
56.Miyoshi Y, Takahashi Y, Egawa C,Noguchi S. Breast J.Breast cancer risk associated with CYP1A1 genetic
polymorphisms in Japanese women. 2002;8:209–15.
57. Basham VM, Pharoah PD, Healey CS, Luben RN, Day NE, Easton DF, Ponder BA, Dunning AM.
Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk. Carcinogenesis.
2001;22:1797–800.
58. Yamaguti GG, Lourenço GJ, SilveiraVS, Tone LG, Lopes LF, Lima CS.Increased risk for acute
lymphoblastic leukemia in children with cytochrome P450A1 (CYP1A1)- andNAD(P)H:quinine
oxidoreductase 1 (NQO1)-inherited gene variants. Acta Haematol. 2010;124:182–4.
59. ClearySP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in
carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol. 2010;172:1000–14.
60. Sabitha K, Reddy MV, Jamil K. Smoking related risk involved in individuals carrying genetic variants of
CYP1A1 gene in head and neckcancer. Cancer Epidemiol. 2010;34:587–92.
61. Rodrigues IS, Kuasne H, Losi-Guembarovski R, Fuganti PE, Gregório EP,Kishima MO, Ito K, de Freitas
Rodrigues MA, de Syllos Cólus IM.Evaluation of the influence of polymorphic variants CYP1A1 2B,
CYP1B1 2, CYP3A4 1B, GSTM1 0, andGSTT1 0 in prostate cancer. Urol Oncol. 2011;29:654–63.
62. Moreno-Galván M, Herrera-González NE, Robles-Pérez V, Velasco-Rodríguez JC, Tapia-Conyer R, Sarti E.
Impact of CYP1A1 and COMT genotypes on breast cancer risk in Mexican women: a pilot study.
Int J Biol Markers. 2010;25:157–63.
63. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD.Cytochrome P4501A1 polymorphism as a susceptibility
factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer. 1999;80:1838–43.
64. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF.Breast cancer and CYPIA1, GSTM1, and
GSTT1 polymorphisms: evidence of a lack of association in Caucasians and AfricanAmericans. Cancer Res.
1998;58:65–70.
65. Kumar V,Yadav CS, Singh S, Goel S, Ahmed RS, Gupta S, Grover RK, Banerjee BD.CYP 1A1
polymorphism and organochlorine pesticides levels in the etiology of prostate cancer. Chemosphere.
2010;81:464–8.
66. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller
MW, Muendlein A, Koelbl H.Estrogen-metabolizing gene polymorphisms in the assessment of breast
carcinoma risk and fibroadenoma risk in Caucasian women. Cancer. 2004;101:264–9.
67. Sugawara T, Nomura E, Sagawa T, Sakuragi N, FujimotoS.CYP1A1 polymorphism and risk of
gynecological malignancy in Japan. Int J Gynecol Cancer. 2003;13:785–90.
68.Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF, Le Marchand L. CYP1A1 genetic polymorphisms
and in situ colorectal cancer. Cancer Res. 1994 Jul 15;54:3692–5.
69. Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J.Susceptibility to endometrial cancer:
influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450
(CYP1A1)loci. Br J Cancer. 1997;75:1385–8.
70. Wang AH, Sun CS, Li LS, Huang JY, Chen QS,Xu DZ.Genetic susceptibility and environmental factors of
esophageal cancer in Xi'an. World J Gastroenterol. 2004;10:940–4.
71. Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX.CYP1A1, GSTs and mEH polymorphisms and
susceptibility to esophageal carcinoma: study of population from a high-incidence area in north China. World
J Gastroenterol. 2003;9:1394–7.
72. Sam SS, Thomas V, Reddy KS, Surianarayanan G,Chandrasekaran A.Gene-gene interactions of drug
metabolizing enzymes and transporter protein in the risk of upperaerodigestive tract cancers among Indians.
Cancer Epidemiol. 2010;34:626–33.
73. Tsuchiya Y, Baez S, Calvo A, Pruyas M, Nakamura K, Kiyohara C, OyamaM, Ikegami K, Yamamoto M.
Evidence that genetic variants of metabolic detoxication and cell cycle control are not related to gallbladder
cancer risk in Chilean women. Int J Biol Markers. 2010;25:75–8.
74. Nisa H, Kono S, Yin G, Toyomura K, Nagano J, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T,
Ikejiri K, Futami K, Maekawa T, Yasunami Y, Takenaka K, Ichimiya H, Terasaka R.Cigarette smoking,
genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study.BMC Cancer.
2010;10:274.
75. Sharma R, Ahuja M, Panda NK, Khullar M.Combined effect of smoking and polymorphisms in tobacco
carcinogen-metabolizing enzymes CYP1A1 andGSTM1 on the head and neck cancer risk in North Indians.
DNACell Biol. 2010;29:441–8.
76. Canova C, Richiardi L, Merletti F, Pentenero M, Gervasio C, Tanturri G, Garzino-Demo P, Pecorari G,
Talamini R, Barzan L, Sulfaro S, Franchini G, Muzzolini C, Bordin S, Pugliese GN, Macrì E, Simonato L.
Alcohol, tobacco and genetic susceptibility in relation to cancers of the upper aerodigestive tract in northern
Italy. Tumori. 2010;96:1–10.
77. Kiss I, Sándor J, Pajkos G, Bogner B, Hegedüs G, Ember I.Colorectal cancer risk in relation to genetic
polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res.
2000;20:519–22.
78. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, ScottRJ.
Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial
cancer risk. Cancer Epidemiol. 2010;34:328–37.
79. HeubnerM, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W.The CYP1A1
Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res. 2010;18:343–7.
80. Kristiansen W, HaugenTB, Witczak O, Andersen JM, Fosså SD, Aschim EL.CYP1A1, CYP3A5 and
CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl. 2011;34:77–83.
81. Ociepa-ZawalM, Rubiś B, Filas V, Breborowicz J, Trzeciak WH.Studies on CYP1A1, CYP1B1 and
CYP3A4 gene polymorphisms in breast cancer patients.Ginekol Pol. 2009;80:819–23.
82. Mota P, Moura DS, Vale MG,Coimbra H, Carvalho L, Regateiro F.CYP1A1 m1 and m2 polymorphisms:
genetic susceptibility to lung cancer. Rev Port Pneumol. 2010;16:89–98.
83.Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, Conway K. Cigarette smoking, cytochrome
P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast Cancer Res.
2004;6:R460–73.
84. Kobayashi M, Otani T, Iwasaki M, Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Sakamoto H, Yoshida T,
Tsugane S.Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2,
CYP1A1,and CYP1A2 and risk of stomach cancer: a hospital-based case–control study in Japan. Gastric
Cancer. 2009;12:198–205.
85. Singh AP, Pant MC, Ruwali M, Shah PP, Prasad R, Mathur N,Parmar D.Polymorphism in cytochrome P450
1A2 and their interaction with risk factors in determining risk ofsquamous cell lung carcinoma in men.
Cancer Biomark. 2010-2011;8:351–9.
86. Sam SS, Thomas V, ReddyKS, Surianarayanan G,Chandrasekaran A.Gene-environment interactions
associated with CYP1A1 MspI and GST polymorphisms and the risk of upperaerodigestive tract cancers in
an Indian population. J Cancer Res Clin Oncol. 2010;136:945–51.
87. Gutman G,Morad T, Peleg B, Peretz C, Bar-Am A, Safra T, Grisaru D.CYP1A1 and CYP2D6 gene
polymorphisms in Israeli Jewish women with cervical cancer. Int J Gynecol Cancer. 2009;19:1300–2.
88. Tai J, Yang M, Ni X, Yu D, Fang J, Tan W, Huang Z, Wu C, Chen X, Wang G, Zhou W, Chen X, Zhang W, Ma
L, Lin D, Han D.Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of
squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet Cytogenet.
2010;196:76–82.
89. Klinchid J,Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R.Effect of combined
genetic polymorphisms on lung cancer risk in northern Thai women.Cancer Genet Cytogenet.
2009;195:143–9.
90.Taioli E, Bradlow HL, Garbers SV, Sepkovic DW,Osborne MP, Trachman J, Ganguly S, Garte SJ.Role of
estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev.
1999;23:232–7.
91. Wu MT, Lee JM, Wu DC, Ho CK, Wang YT, Lee YC, Hsu HK, Kao EL.Genetic polymorphisms of
cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan. Br J Cancer.
2002;87:529–32.
92. Wang AH, Sun CS, Li LS, Huang JY, Chen QS. Relationship of tobacco smoking CYP1A1 GSTM1 gene
polymorphism and esophageal cancer in Xi'an. World J Gastroenterol. 2002;8:49–53.
93. Kim HN, Kim NY, Yu L, Kim YK, Lee IK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, Kim HJ.
Polymorphisms of drug-metabolizing genes and risk of non-Hodgkin lymphoma. Am J Hematol.
2009;84:821–5.
94. Schneider J, Bernges U.CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with
pneumoconiosis and occupationally related tumours: A pilot study. Mol Med Report. 2009;2:1023–8.
95. Zhang H, Sun C, Li L, Yan M. Cytochrome P450IA1 and the genetic susceptibility to esophageal carcinoma.
Zhonghua Yu Fang Yi Xue Za Zhi. 2000;34:69–71.
96. Shaffi SM, Shah MA,Bhat IA, Koul P, Ahmad SN, Siddiqi MA. CYP1A1 polymorphisms and risk of lung
cancer in the ethnic Kashmiri population. Asian Pac J Cancer Prev. 2009;10:651–6.
97. Ferlin A, Ganz F, Pengo M, Selice R, Frigo AC, Foresta C.Association of testicular germ cell tumor with
polymorphisms in estrogen receptor and steroid metabolismgenes. Endocr Relat Cancer. 2010;17:17–25.
98. Shao G, Su Y, Huang G, Wen B.Relationship between CYP1A1, GSTM1 genetic polymorphisms and
susceptibility to esophageal squamous cell carcinoma.Zhonghua Liu Xing Bing Xue Za Zhi.2000;21:420–3.
99. Chatterjee S, Chakrabarti S, Sengupta B, Poddar S, Biswas D, Sengupta S, Talukder G.Prevalence of
CYP1A1 and GST polymorphisms in the population of northeastern India and susceptibility oforal cancer.
OncolRes.2009;17:397–403.
100.van Lieshout EM, Roelofs HM, Dekker S, Mulder CJ, Wobbes T, Jansen JB, Peters WH.Polymorphic
expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and
esophageal carcinoma. Cancer Res. 1999;59:586–9.
101.Hori H, Kawano T, Endo M, Yuasa Y.Genetic polymorphisms of tobacco- and alcohol-related metabolizing
enzymes and human esophageal squamous cell carcinoma susceptibility. J Clin Gastroenterol.
1997;25:568–75.
102. SinghAP, Shah PP, Ruwali M, Mathur N, Pant MC, Parmar D.Polymorphism in cytochrome P4501A1 is
significantly associated with head and neck cancer risk. Cancer Invest. 2009;27:869–76.
103. Wright CM, Larsen JE, Colosimo ML, Barr JJ, Chen L, McLachlan RE, Yang IA, Bowman RV,Fong KM.
Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lungcancer.
Eur Respir J. 2010;35:152–9.
104. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T. Genetic
polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer.
1999;83:606–9.
105. Nimura Y, Yokoyama S, Fujimori M, Aoki T, Adachi W, Nasu T, He M, Ping YM, Iida F. Genotyping of the
CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking.Cancer.
1997;80:852–7.
106. Morita S, Yano M, Shiozaki H, Tsujinaka T, Ebisui C, Morimoto T, Kishibuti M, Fujita J, Ogawa A, Taniguchi
M, InoueM, Tamura S, Yamazaki K, Kikkawa N, Mizunoya S, Monden M.CYP1A1, CYP2E1 and GSTM1
polymorphisms are not associated with susceptibility to squamous-cell carcinoma of theesophagus. Int J
Cancer. 1997;71:192–5.
107. Suzuki S, Muroishi Y, Nakanishi I, Oda Y.Relationship between genetic polymorphisms of drug-metabolizing
enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point
mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39:220–30.